LifeLine Northern Cape

WORLD POPULATION DAY🌎

Today we reflect on the importance of building healthier, safer, and more sustainable communities for everyone.

World Population Day highlights the need for access
to healthcare, education, equality, family planning, and opportunities that improve the quality of life for people around the world

Every person matters, and together we can create a future where everyone has the chance to thrive with dignity, health, and hope.

Let’s continue to support:
✔ Quality healthcare for all
✔ Education and empowerment
✔ Gender equality
✔ Healthy families and communities
✔ Sustainable development
A better future starts with caring for people today.

🚫 PUBLIC WARNING‼️‼️
Health regulators warn against the use or dispensing of recalled Semaglutide and Tirzepatide
https://www.sahpra.org.za/document/idexis-semaglutide-idexis-tirzepatide-idexissemaglutide-tirzepatide/
The South African Pharmacy Council (SAPC), Health Professions Council of South Africa (HPCSA) and the South African Health Products Regulatory Authority (SAHPRA) hereby warn the public, pharmacies and dispensing medical practitioners against any continued use, prescription and/or dispensing of iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide recalled by SAHPRA in June 2026.

The continued use, prescription and dispensing of these products pose a severe risk to patients’ safety and/or users. Any healthcare professional found to have dispensed, prescribed or kept stock of the recalled products will face disciplinary action in accordance with applicable legislation, including the Medicines and Related Substances Act, 101 of 1965.

In a Class I, Type A Recall, SAHPRA determined that iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide pose serious safety risk to patients. Thus, any professional found to be prescribing or dispensing them to patients or users will knowingly be endangering the health of the public.
The recall notice, which contains a list of the recalled products, may be accessed at: https://www.sahpra.org.za/document/idexis-semaglutide-idexis-tirzepatide-idexissemaglutide-tirzepatide/

Issued by:

1. Mr Vincent Tlala, Registrar/CEO, South African Pharmacy Council

2. ⁠Dr Boitumelo Semete-Makokotlela, CEO, South African Health Product Authority

3. ⁠Dr Karmani S Chetty, Interim Registrar, Health Professions Council of South Africa

Click this link to view the media release: https://sapc.za.org/Media_Releases

This Mental Illness Awareness Month, let’s continue breaking the stigma, encouraging open conversations, and reminding one another that asking for help is a sign of courage, not weakness.

Start this week with hope. End it with strength.

|
Quitting Is Possible

Dagga may seem harmless, but it can have serious effects on your mental health, especially for teenagers and young adults.

🧠 It can affect brain development, memory, concentration, and learning.
📖 It can reduce academic performance and motivation.
💬 It can increase the risk of mental health problems, including anxiety, depression, and psychosis, particularly in those who are vulnerable.
🚫 It can lead to cannabis use disorder (dependence), making it difficult to stop using.
⚠️ It can impair judgement and decision-making, increasing the risk of accidents and other risky behaviours.

Quitting is possible, and recovery is within reach. With the right support, treatment, and determination, many people successfully overcome cannabis dependence and go on to live healthy, drug-free lives.

Protect your future. Choose health.
🚫 Say NO to substance abuse‼️



Department of Social Development Department of Basic Education

LifeLine SouthAfrica